A Total of 37,777.70 DMD Has Been Permanently Burned Over the Past 7 Days
According to the latest on-chain data released by DMDAO, over the past seven calendar days, a total of 37,777.70 DMD has been permanently burned through the protocol's established trading and wealth management burn mechanism.
Moving Toward the Target Supply:As the burn process continues, DMD is steadily converging toward its target maximum supply of 1,000,000 tokens. With the ongoing circulation of on-chain transactions and protocol mechanisms, the overall circulating supply in the market is being gradually reduced.
Operational Performance:The consistent accumulation of burn data directly reflects the recent performance of the protocol's underlying market-making system in capturing high-frequency on-chain spreads, as well as its genuine business activity. Driven by the deflationary model, the continued reduction in circulating supply helps enhance the value-carrying capacity of the remaining circulating tokens.
Market Liquidity Outlook:As the public market trading pairs continue to operate steadily, DMD is gradually integrating into the broader secondary market. This not only introduces a more diversified base of external participants to the ecosystem, but also contributes to strengthening the long-term stability of the liquidity pool and expanding the overall growth potential of the ecosystem.
The deflationary mechanism continues to operate, while the market structure is being steadily optimized. DMDAO will continue to maintain transparent disclosure of all relevant data.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Analyst Gu Jingci: Follow the trend and adapt flexibly
XRP Ledger adds account control feature, enabling enterprises to manage assets offline.
BUZZ - Goldman Sachs says the price cap on cancer drugs has limited impact on Indian hospitals
October 9 – Goldman Sachs pointed out that India's implementation of a 30% profit margin cap on non-scheduled anticancer drugs (link) will have limited impact on hospitals. The report states that, based on preliminary discussions with hospital chain groups, such drugs account for less than 5% of hospital revenue and 2% to 2.5% of operating profit. The report adds that hospitals can offset the losses by slightly adjusting service charges, such as administration fees. According to a government notice, an expert committee will finalize the list of drugs to be brought under regulation. Driven by the anticipated price cap, the share prices of Max Healthcare MAXE.NS, Apollo Hospitals APLH.NS, and Fortis Healthcare FOHE.NS rose by 1.6% to 2.5%. Previously, since September 30, these stocks had collectively declined by 11% to 11.5%. Year-to-date, FOHE and MAXE are down 11.7% and 14.8%, respectively, while APLH has risen by 11%. (To assist non-English speakers, Reuters provides automated translations of its reports into several other languages. Due to potential errors or missing context in automated translations, Reuters does not guarantee the accuracy of automatic translation texts and offers them solely for readers’ convenience. Reuters accepts no responsibility for any damage or loss caused by using these automated translation features.)
Adding insult to injury! Japanese electronics giant Nidec downgraded by UBS, stock price plunges over 9% and approaches an 11-month low
UBS has downgraded Nidec's rating from "Buy" to "Neutral" and lowered its target price from 2,800 yen to 2,400 yen, citing a more challenging market environment.
Crypto prices
More
